Ballentine Partners LLC Purchases New Holdings in GoodRx Holdings, Inc. $GDRX

Ballentine Partners LLC purchased a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 24,374 shares of the company’s stock, valued at approximately $121,000.

A number of other large investors also recently bought and sold shares of GDRX. Deutsche Bank AG purchased a new position in GoodRx during the 4th quarter valued at about $137,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in GoodRx by 70.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 149,945 shares of the company’s stock worth $697,000 after buying an additional 61,924 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in GoodRx by 12.2% in the first quarter. Assenagon Asset Management S.A. now owns 362,713 shares of the company’s stock worth $1,600,000 after buying an additional 39,337 shares during the last quarter. CWA Asset Management Group LLC purchased a new position in GoodRx in the first quarter worth about $292,000. Finally, Teacher Retirement System of Texas purchased a new position in GoodRx in the first quarter worth about $218,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $6.00 target price on shares of GoodRx in a report on Monday, August 11th. Raymond James Financial cut shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.80.

Insider Transactions at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $4.05, for a total value of $64,864.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.17% of the company’s stock.

GoodRx Stock Performance

Shares of NASDAQ GDRX opened at $4.23 on Wednesday. The firm has a 50 day moving average of $4.27 and a 200 day moving average of $4.39. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 42.30, a price-to-earnings-growth ratio of 1.87 and a beta of 1.23. GoodRx Holdings, Inc. has a 12-month low of $3.31 and a 12-month high of $7.20.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). The business had revenue of $203.07 million for the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.08 earnings per share. On average, research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.